These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America. Colli JL; Amling CL Prostate Cancer Prostatic Dis; 2008; 11(3):247-51. PubMed ID: 18268527 [TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. Welch HG; Schwartz LM; Woloshin S J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071 [TBL] [Abstract][Full Text] [Related]
5. Screening for prostate cancer. Brawley OW; Ankerst DP; Thompson IM CA Cancer J Clin; 2009; 59(4):264-73. PubMed ID: 19564245 [TBL] [Abstract][Full Text] [Related]
6. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important? Barry MJ; Mulley AJ J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451 [No Abstract] [Full Text] [Related]
7. Prostate cancer screening; is this a teachable moment? Brawley OW J Natl Cancer Inst; 2009 Oct; 101(19):1295-7. PubMed ID: 19720970 [No Abstract] [Full Text] [Related]
8. Prostate cancer: a review of common underwriting problems, Part 1. Richie RC; Swanson JO J Insur Med; 2004; 36(3):242-54. PubMed ID: 15495440 [TBL] [Abstract][Full Text] [Related]
9. [PSA based screening for prostatic cancer]. Johansen TE Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357 [No Abstract] [Full Text] [Related]
10. Prostate cancer: is the PSA test the answer? Berlin B N J Med; 1998 Mar; 95(3):53-5. PubMed ID: 16013148 [No Abstract] [Full Text] [Related]
11. [Prostate cancer and prostate specific antigen screening]. Camici M Minerva Med; 2004 Feb; 95(1):25-34. PubMed ID: 15041924 [TBL] [Abstract][Full Text] [Related]
12. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Telesca D; Etzioni R; Gulati R Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937 [TBL] [Abstract][Full Text] [Related]
13. Screening for prostate cancer: current recommendations. Wilson SS; Crawford ED Urol Clin North Am; 2004 May; 31(2):219-26. PubMed ID: 15123402 [TBL] [Abstract][Full Text] [Related]
14. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening. Porter MP; Stanford JL; Lange PH Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738 [TBL] [Abstract][Full Text] [Related]
15. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Etzioni R; Gulati R; Falcon S; Penson DF Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508 [TBL] [Abstract][Full Text] [Related]
16. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer]. Zhao XJ; Kong XB; Wang WH Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882 [TBL] [Abstract][Full Text] [Related]
18. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Vutuc C; Schernhammer ES; Haidinger G; Waldhör T Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872 [TBL] [Abstract][Full Text] [Related]
19. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Shaw PA; Etzioni R; Zeliadt SB; Mariotto A; Karnofski K; Penson DF; Weiss NS; Feuer EJ Am J Epidemiol; 2004 Dec; 160(11):1059-69. PubMed ID: 15561985 [TBL] [Abstract][Full Text] [Related]
20. What is the value of screening for prostate cancer in the US? Albertsen PC Nat Clin Pract Oncol; 2005 Nov; 2(11):536-7. PubMed ID: 16270077 [No Abstract] [Full Text] [Related] [Next] [New Search]